The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Total costs of therapy with lenalidomide or bortezomib in relapsed/refractory multiple myeloma (rrMM).
Ivan Borrello
Consultant or Advisory Role - Celgene
Honoraria - Celgene
Research Funding - Celgene
Gary Binder
Employment or Leadership Position - Celgene
Stock Ownership - Celgene
Zeba M. Khan
Employment or Leadership Position - Celgene
Stock Ownership - Celgene
Chris L Pashos
Research Funding - Celgene
Brian G. Durie
Honoraria - Celgene; Millennium; Onyx